Literature DB >> 12539187

Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry.

Jean-Claude Wolff1, Linda A Thomson, Christine Eckers.   

Abstract

Methodology is presented for identifying an unknown active (pharmaceutical) ingredient (AI) in a counterfeit drug product. A range of mass spectrometric techniques, i.e., accurate mass mass spectrometry, tandem mass spectrometry (MS/MS) and liquid chromatography/mass spectrometry (LC/MS), has been employed to determine the AI in a counterfeit Halfan suspension, an antimalarial drug. In particular, use of LockSpray accurate mass MS/MS allowed identification of parts of the molecule from fragments, hence limiting the number of possible elemental compositions for the nominal mass of 278 found for the AI in the counterfeit product. The analysis of the isotope pattern observed for the protonated molecule further reduced the number of possible elemental compositions. A literature search for readily commercially available compounds of molecular formula C(12)H(14)N(4)O(2)S suggested that the AI was either sulfamethazine or sulfisomidine. An LC/MS separation of those two compounds and reference MS/MS spectra obtained for sulfamethazine and sulfisomidine led to the conclusion that the AI in the counterfeit Halfan suspension is sulfamethazine, which is an antibacterial agent. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12539187     DOI: 10.1002/rcm.893

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  6 in total

Review 1.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

2.  Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries.

Authors:  Facundo M Fernandez; Dana Hostetler; Kristen Powell; Harparkash Kaur; Michael D Green; Dallas C Mildenhall; Paul N Newton
Journal:  Analyst       Date:  2010-11-25       Impact factor: 4.616

Review 3.  Antimalarial drug quality in Africa.

Authors:  A A Amin; G O Kokwaro
Journal:  J Clin Pharm Ther       Date:  2007-10       Impact factor: 2.512

4.  Poor quality vital anti-malarials in Africa - an urgent neglected public health priority.

Authors:  Paul N Newton; Michael D Green; Dallas C Mildenhall; Aline Plançon; Henry Nettey; Leonard Nyadong; Dana M Hostetler; Isabel Swamidoss; Glenn A Harris; Kristen Powell; Ans E Timmermans; Abdinasir A Amin; Stephen K Opuni; Serge Barbereau; Claude Faurant; Ray C W Soong; Kevin Faure; Jonarthan Thevanayagam; Peter Fernandes; Harparkash Kaur; Brian Angus; Kasia Stepniewska; Philippe J Guerin; Facundo M Fernández
Journal:  Malar J       Date:  2011-12-13       Impact factor: 2.979

5.  Mind the gaps--the epidemiology of poor-quality anti-malarials in the malarious world--analysis of the WorldWide Antimalarial Resistance Network database.

Authors:  Patricia Tabernero; Facundo M Fernández; Michael Green; Philippe J Guerin; Paul N Newton
Journal:  Malar J       Date:  2014-04-08       Impact factor: 2.979

6.  The global threat of counterfeit drugs: why industry and governments must communicate the dangers.

Authors:  Robert Cockburn; Paul N Newton; E Kyeremateng Agyarko; Dora Akunyili; Nicholas J White
Journal:  PLoS Med       Date:  2005-03-14       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.